<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003273</url>
  </required_header>
  <id_info>
    <org_study_id>IECPG-164</org_study_id>
    <nct_id>NCT03003273</nct_id>
  </id_info>
  <brief_title>Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study</brief_title>
  <acronym>DALFEN</acronym>
  <official_title>Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: a Randomized Controlled Study -DALFEN Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric patients with febrile neutropenia coming to Department of Medical Oncology with low
      risk features (culture awaited), will be started on intravenous antibiotics (Inj
      Cefoperazone+ Sulbactam ± Amikacin) on outpatient basis. Those patients will be reassessed
      for randomization once they fulfill all inclusion criteria and get afebrile for at least 24
      hours. Antibiotics will be stopped in Arm-A and oral antibiotics, in place of intravenous
      antibiotics, will be started in Arm-B. The patients will be followed-up till ANC≥ 500, or
      reappearance of fever within follow-up of ≤ 10 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment is considered to be successful if the following is attained without changing the regimen - Patient remains afebrile till recovery of ANC ≥500 •Measure of effect: Proportion of patients afebrile in each arm</measure>
    <time_frame>till ANC ≥ 500 or reappearance of fever during the period ≤ 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of re-admission</measure>
    <time_frame>till ANC ≥ 500 or reappearance of fever during the period ≤10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Neutropenia, Febrile</condition>
  <condition>Pediatric Cancer</condition>
  <arm_group>
    <arm_group_label>arm (A) - stoppage of antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm (B) - oral antibiotics till ANC ≥ 500</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stoppage of antibiotics</intervention_name>
    <description>antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.</description>
    <arm_group_label>arm (A) - stoppage of antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>amoxycillin/clavulanic acid</intervention_name>
    <description>In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)</description>
    <arm_group_label>arm (B) - oral antibiotics till ANC ≥ 500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
    <description>In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)</description>
    <arm_group_label>arm (B) - oral antibiotics till ANC ≥ 500</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All pediatric febrile neutropenia patients treated on outpatient basis

          -  Age 3 years - 18 years

          -  Fulfilling low risk criteria ( Hematological malignancies in remission, No
             identifiable focus of infection, No Pneumonia/ mucositis / GI sepsis /
             Nausea-vomiting/ neurologic-mental status changes/ Central Venous Catheter (CVC)
             related infection, Anticipated Absolute Neutrophil Count (ANC) recovery ≤ 10 days, No
             organ dysfunction, Hemodynamically stable, Culture negative )

          -  Afebrile for at least 24 hours, on intra-venous antibiotics

        Exclusion Criteria:

          -  Bone marrow involvement in solid tumor

          -  Already enrolled once, in previous episode

          -  On antibiotics prophylaxis

          -  Retroviral positive patients

          -  Patient undergone stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameer Bakhshi, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Medical Oncology, 2nd Floor, B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SAMEER BAKHSHI, Professor</last_name>
    <phone>011-29575237</phone>
    <email>sambakh@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Akash Kumar, MD</last_name>
    <phone>919910850134</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medical Oncology, AIIMS</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sameer Bakhshi, MD</last_name>
      <phone>011-29575237</phone>
      <email>sambakh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>AKASH KUMAR</investigator_full_name>
    <investigator_title>Senior Resident (DM course)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

